Literature DB >> 10942601

Epidermal growth factor receptor signaling activates met in human anaplastic thyroid carcinoma cells.

J D Bergström1, B Westermark, N E Heldin.   

Abstract

Overexpression of Met is a common finding in thyroid carcinomas. Recently, we reported on overexpression and ligand-independent constitutive activation of Met in anaplastic thyroid carcinoma cells. In the present study we have investigated a putative mechanism for this phenomenon. Cell lines with constitutively activated Met expressed both TGF-alpha mRNA and protein. Western blot analysis revealed expression of receptors for epidermal growth factor (EGFR) in all carcinoma cell lines; in tumor cells with elevated levels of TGF-alpha mRNA there was a constitutive tyrosine phosphorylation of the EGFRs. Preincubation of carcinoma cells with suramin decreased EGFR activation and downregulated Met expression as well as the ligand-independent phosphorylation of Met. Similar results were obtained with a EGFR tyrosine kinase inhibitor, AG 1478. The MEK inhibitor U0126 had an even more pronounced effect compared to AG 1478, indicating a Ras/MAPK-mediated signal in the regulation of Met expression and activation. Inhibition of EGFR signaling also decreased proliferation of the anaplastic thyroid carcinoma cells. Thus, aberrant activation of EGFRs may lead to an overexpression and activation of Met, which may be of importance for the malignant phenotype of anaplastic thyroid carcinomas. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10942601     DOI: 10.1006/excr.2000.4967

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  37 in total

Review 1.  Mechanisms of HGF/Met signaling to Brk and Sam68 in breast cancer progression.

Authors:  Alessia Locatelli; Kristopher A Lofgren; Andrea R Daniel; Nancy E Castro; Carol A Lange
Journal:  Horm Cancer       Date:  2012-04       Impact factor: 3.869

2.  Endothelial PAS domain-containing protein 1 confers TKI-resistance by mediating EGFR and MET pathways in non-small cell lung cancer cells.

Authors:  Qiang Zhen; Jun-Feng Liu; Jia-Bao Liu; Ren-Feng Wang; Wei-Wei Chu; Ya-Xiao Zhang; Guo-Liang Tan; Xiao-Jian Zhao; Bao-Lei Lv
Journal:  Cancer Biol Ther       Date:  2015-04-01       Impact factor: 4.742

3.  Phosphotyrosine profiling of NSCLC cells in response to EGF and HGF reveals network specific mediators of invasion.

Authors:  Hannah Johnson; Rebecca S Lescarbeau; Jesus A Gutierrez; Forest M White
Journal:  J Proteome Res       Date:  2013-03-11       Impact factor: 4.466

4.  Anaplastic thyroid carcinoma: A comprehensive review of current and future therapeutic options.

Authors:  Francesco Perri; Giuseppe Di Lorenzo; Giuseppina Della Vittoria Scarpati; Carlo Buonerba
Journal:  World J Clin Oncol       Date:  2011-03-10

5.  The RTK Interactome: Overview and Perspective on RTK Heterointeractions.

Authors:  Michael D Paul; Kalina Hristova
Journal:  Chem Rev       Date:  2018-12-27       Impact factor: 60.622

6.  Differential effects of cetuximab and AEE 788 on epidermal growth factor receptor (EGF-R) and vascular endothelial growth factor receptor (VEGF-R) in thyroid cancer cell lines.

Authors:  S Hoffmann; A Burchert; A Wunderlich; Y Wang; S Lingelbach; L C Hofbauer; M Rothmund; A Zielke
Journal:  Endocrine       Date:  2007-04       Impact factor: 3.633

7.  Ligand-independent activation of MET through IGF-1/IGF-1R signaling.

Authors:  Andreas Varkaris; Sanchaika Gaur; Nila U Parikh; Jian H Song; Farshid Dayyani; Jung-Kang Jin; Christopher J Logothetis; Gary E Gallick
Journal:  Int J Cancer       Date:  2013-04-17       Impact factor: 7.396

8.  Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition.

Authors:  Simona Corso; Elena Ghiso; Virna Cepero; J Rafael Sierra; Cristina Migliore; Andrea Bertotti; Livio Trusolino; Paolo M Comoglio; Silvia Giordano
Journal:  Mol Cancer       Date:  2010-05-26       Impact factor: 27.401

9.  EGFR/Met association regulates EGFR TKI resistance in breast cancer.

Authors:  Kelly L Mueller; Zeng-Quan Yang; Ramsi Haddad; Stephen P Ethier; Julie L Boerner
Journal:  J Mol Signal       Date:  2010-07-12

10.  Epidermal growth factor receptor plays a significant role in hepatocyte growth factor mediated biological responses in mammary epithelial cells.

Authors:  Alyssa R Bonine-Summers; Mary E Aakre; Kimberly A Brown; Carlos L Arteaga; Jennifer A Pietenpol; Harold L Moses; Nikki Cheng
Journal:  Cancer Biol Ther       Date:  2007-04       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.